Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 04'th Apr 2025
SOUTH SAN FRANCISCO, Calif. , April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc.
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation
08:05am, Thursday, 27'th Mar 2025
SOUTH SAN FRANCISCO, Calif. , March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd.
Rigel Appoints Mark W. Frohlich, M.D.
08:05am, Monday, 10'th Mar 2025
SOUTH SAN FRANCISCO, Calif. , March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W.
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade
10:56am, Wednesday, 05'th Mar 2025
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript
11:29pm, Tuesday, 04'th Mar 2025
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. R
Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates
06:15pm, Tuesday, 04'th Mar 2025
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to break-even earnings per share a year ago.
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 04'th Mar 2025
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
02:45pm, Tuesday, 25'th Feb 2025
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfo
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
08:05am, Tuesday, 25'th Feb 2025
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results afte
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
11:10am, Monday, 24'th Feb 2025
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth.
4 Healthcare Stocks to Buy as the Sector Stages a Comeback
09:15am, Monday, 24'th Feb 2025
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.
Does Rigel (RIGL) Have the Potential to Rally 40.88% as Wall Street Analysts Expect?
10:55am, Monday, 03'rd Feb 2025
The mean of analysts' price targets for Rigel (RIGL) points to a 40.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease
08:05am, Wednesday, 22'nd Jan 2025
First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know
10:56am, Friday, 17'th Jan 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive
Best Momentum Stock to Buy for January 17th
08:51am, Friday, 17'th Jan 2025
WFC, FHN and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2025.
